Holiday Sale | Save 50%
SubscribeLogin
Holiday Sale | Save 50%
Published

#Savara Inc. Submits FDA Application for MOLBREEVI to Treat Autoimmune Pulmonary Alveolar Proteinosis Follow...

Summary by csimarket.com
Savara Inc. Advances Toward Regulatory Approval for MOLBREEVI: Pioneering Treatment for Rare Lung Disease In an exciting development for patients with a rare and debilitating lung condition, Savara Inc., a clinical-stage biopharmaceutical company based in Langhorne, Pennsylvania, has initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its lead product, MOLBREEVI. This innovat…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

LanghorneLanghorne
Trending Topics
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal